COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

 

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

COMPASS Pathways launches phase 2 clinical trial of psilocybin therapy in anorexia nervosa

 

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Letter from Kabir Nath, our new CEO from August 1, 2022

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

Our annual review 2021

In 2021 we we took a giant leap forward in our work to transform mental health care. Read about our progress.

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

A New Year message to our community

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

COMPASS selected for addition to NASDAQ Biotechnology Index

COMPASS Pathways announces changes in Executive Team

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

COMPASS Pathways is granted new US patent for crystalline psilocybin

COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020

COMPASS Pathways News | December 2020 Issue

Our highlights in the second half of 2020 as we work towards building a world of mental wellbeing for everyone.